Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agilon Health (AGL) EBITDA (2020 - 2025)

Agilon Health (AGL) has disclosed EBITDA for 6 consecutive years, with -$203.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 76.78% year-over-year to -$203.8 million, compared with a TTM value of -$461.7 million through Dec 2025, down 58.93%, and an annual FY2025 reading of -$461.7 million, down 58.98% over the prior year.
  • EBITDA was -$203.8 million for Q4 2025 at Agilon Health, down from -$127.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $2.1 million in Q1 2023 and bottomed at -$297.8 million in Q2 2021.
  • Average EBITDA over 5 years is -$72.5 million, with a median of -$36.1 million recorded in 2021.
  • The sharpest move saw EBITDA plummeted 39496.14% in 2021, then soared 5023.26% in 2023.
  • Year by year, EBITDA stood at -$25.7 million in 2021, then tumbled by 106.0% to -$52.9 million in 2022, then crashed by 209.09% to -$163.4 million in 2023, then increased by 29.44% to -$115.3 million in 2024, then plummeted by 76.78% to -$203.8 million in 2025.
  • Business Quant data shows EBITDA for AGL at -$203.8 million in Q4 2025, -$127.5 million in Q3 2025, and -$112.1 million in Q2 2025.